Management of Facial Infantile Hemangiomas

Timing and Referral

• The proliferative phase of facial infantile hemangiomas peaks between 1 – 3 months of age, making early identification essential. 1
• Referral to a hemangioma specialist should occur by 1 month of age for any facial lesion to allow treatment within the optimal window. 1

Pharmacologic Therapy

First‑Line Systemic Treatment

• Oral propranolol, initiated at 1 mg/kg/day and titrated to a maintenance dose of 2 – 3 mg/kg/day divided into 2 – 3 doses, is the definitive first‑line therapy for facial infantile hemangiomas that require intervention. 2
• Treatment should begin as early as possible, ideally before the end of the first month of life, to minimize permanent disfigurement. 1

Pre‑Treatment Screening for Segmental Lesions

• All patients with segmental facial hemangiomas must undergo an electrocardiogram and echocardiogram interpreted by a pediatric cardiologist before starting propranolol. 2
• A cerebral magnetic resonance angiogram is recommended for segmental head/neck lesions to screen for PHACE‑associated arteriopathy; if urgent MRA is unavailable, propranolol may be started at a reduced dose of 0.5 mg/kg/day in three divided doses. 2

Monitoring and Safety

• Blood‑glucose monitoring is required only for infants who are preterm, have low birth weight, or have feeding difficulties. 2
• Parents should ensure regular feeding; propranolol should be discontinued during periods of reduced oral intake due to illness. 2
• Routine blood‑pressure and heart‑rate checks are not needed between scheduled visits in clinically stable patients. 2
• Clinical review is recommended 2 – 3 months after therapy initiation, with dose adjustments based on weight change or parental input using written instructions. 2

Topical Therapy for Small Superficial Lesions

• Topical timolol is an effective alternative for small, thin, superficial facial hemangiomas when systemic therapy is not indicated. 1

Risk Assessment and Associated Syndromes

• Large segmental facial hemangiomas warrant evaluation for PHACE syndrome (posterior fossa malformations, arterial anomalies, cardiac defects, eye abnormalities). 2
• Failure to recognize PHACE risk may miss critical structural anomalies requiring multidisciplinary management. 2

Adjunctive Therapies

• Laser and surgical interventions are primarily reserved for residual skin changes after involution rather than for primary lesion removal. 1
• Baseline clinical photographs should be obtained at treatment initiation to document appearance and facilitate monitoring of response. 2

Long‑Term Outcomes

• Approximately 90 % of hemangioma involution is complete by 4 years of age; this timeline allows clinicians to assess the need for laser or surgical consultation for residual changes. 3
• Thick or deep hemangiomas are more likely to leave permanent skin alterations (e.g., telangiectasias, redundant skin, scarring) that can be life‑altering if not addressed early. 1

Implementation Strategies

• Telemedicine triage using photographic assessment can reduce the age at first specialist evaluation from a median of 5.9 months to 3.5 months when access to in‑person care is limited. 3

The strength of evidence for the above recommendations is not explicitly graded in the cited sources.

Guidelines for Management of Congenital Facial Hemangioma

Referral and Critical Timing

• Refer infants with facial hemangioma to a specialist by 1 month of age; early referral enables timely initiation of therapy and reduces risk of permanent scarring. 4
• The most rapid proliferative phase occurs between 1 and 3 months of age, with growth usually completing by 5 months; therefore treatment should be started as early as possible, ideally before the end of the first month. 4, 5
• Early intervention (by 1 month) is associated with better cosmetic and functional outcomes compared with later treatment. 4, 6

Risk Stratification

• Facial hemangiomas are classified as high‑risk lesions that generally require active intervention to prevent disfigurement. 4, 7
• Any involvement of the nasal tip or lip, regardless of size, mandates treatment because of the high aesthetic and functional impact. 7
• Lesions measuring ≥2 cm on the face (or >1 cm in infants ≤3 months) meet criteria for treatment. 7
• Segmental facial hemangiomas carry the greatest risk of permanent scarring and disfigurement and should be managed aggressively. 7
• Large segmental facial hemangiomas may be a manifestation of PHACE syndrome; patients should undergo targeted evaluation for posterior fossa malformations, arterial anomalies, cardiac defects, and ocular abnormalities. 4, 8

First‑Line Systemic Therapy

• Oral propranolol is the drug of choice for systemic treatment of facial infantile hemangiomas. 4, 5
• Recommended dose: 2–3 mg/kg/day, divided into two or three doses. 4, 8
• Treatment duration: at least 6 months, typically continued until 12 months of age (or longer if needed) to minimise relapse. 4, 6

Alternative Medical Options

• Topical timolol can be considered for small, thin, superficial facial hemangiomas when systemic therapy is not required. 4, 6

Surgical and Laser Management

• Surgery or laser therapy is reserved for residual skin changes after involution rather than for primary lesion removal. 4

Common Pitfalls and Recommendations

• Delayed referral beyond 1 month often misses the optimal treatment window, leading to higher risk of permanent disfigurement. 4, 5
• Under‑recognising the risk of even small facial lesions (e.g., nasal tip or lip) may result in undertreatment; these locations always require therapy. 7
• Failure to screen for PHACE syndrome in infants with large segmental facial hemangiomas can miss associated structural anomalies; appropriate imaging and multidisciplinary assessment are essential. 4, 7